- Trials with a EudraCT protocol (17)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
17 result(s) found for: Asthma AND Triamcinolone Acetonide.
Displaying page 1 of 1.
EudraCT Number: 2016-000357-12 | Sponsor Protocol Number: DYNAMO1 | Start Date*: 2016-05-26 |
Sponsor Name:Stichting Longgeneeskunde Fryslan | ||
Full Title: The role of dynamic hyperinflation in asthma | ||
Medical condition: Asthma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-005615-26 | Sponsor Protocol Number: P05365 | Start Date*: 2008-05-30 | |||||||||||
Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation | |||||||||||||
Full Title: Safety of SCH 527123 in Subjects with Neutrophilic Asthma | |||||||||||||
Medical condition: Neutrophilic Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GR (Completed) GB (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001713-42 | Sponsor Protocol Number: B2C109575 | Start Date*: 2007-12-27 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, parallel group, dose ranging study evaluating the efficacy and safety of GW642444M administered once daily compared with placebo for 28 days in adole... | |||||||||||||
Medical condition: Persistent Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FR (Completed) DE (Completed) BE (Completed) PL (Ongoing) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-005058-30 | Sponsor Protocol Number: ODS100207 | Start Date*: 2005-06-29 | |||||||||||
Sponsor Name:GlaxoSmithKline R&D Limited | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 500µg of GW799943X administered once-daily in the morning, 500µg of GW799943X administer... | |||||||||||||
Medical condition: Out-patients with persistent bronchial asthma, currently symptomatic on low dose inhaled corticosteroids. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004583-38 | Sponsor Protocol Number: P08212 | Start Date*: 2015-05-06 |
Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation | ||
Full Title: An Open-Label Study to Assess the Safety and Tolerability of Zenhale® (a Fixed-Dose Combination of Mometasone Furoate/Formoterol Fumarate Delivered by Metered Dose Inhaler) in 40 Subjects with Pers... | ||
Medical condition: Persistent Asthma | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2010-018315-15 | Sponsor Protocol Number: D589GC00001 | Start Date*: 2010-06-09 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase 2, double-blind, randomized, parallel-group, placebo-controlled, multicenter study, comparing budesonide pMDI 160 μg bid with placebo, a 6-week efficacy and safety study in children aged 6 ... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Prematurely Ended) LV (Completed) HU (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018316-32 | Sponsor Protocol Number: D589GC00002 | Start Date*: 2010-11-23 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase 2, randomized, blinded, 5-period cross-over, placebo and activecontrolled, multicenter, dose-finding study of single doses of formoterol 2.25 μg, 4.5 μg, and 9 μg delivered via Symbicort pM... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004459-13 | Sponsor Protocol Number: FFA109685 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
Full Title: A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Flutic... | |||||||||||||
Medical condition: Persistent asthma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) EE (Completed) GR (Completed) SK (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004458-98 | Sponsor Protocol Number: FFA109684 | Start Date*: 2008-01-17 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
Full Title: A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Flutica... | |||||||||||||
Medical condition: Persistent asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) NL (Completed) PL (Completed) EE (Completed) CZ (Completed) BG (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004638-40 | Sponsor Protocol Number: D3250C00025 | Start Date*: 2020-02-14 | |||||||||||
Sponsor Name:AstraZenenca AB | |||||||||||||
Full Title: An Open-label Study to Evaluate the Pharmacokinetics and Pharmacodynamics and Long-term Safety of Benralizumab Administered Subcutaneously in Children with Severe Eosinophilic Asthma. | |||||||||||||
Medical condition: Severe Eosinophilic Asthma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004883-12 | Sponsor Protocol Number: ADA109057 | Start Date*: 2016-12-08 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in ... | ||
Medical condition: Asthma | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2008-007504-28 | Sponsor Protocol Number: SCH-P#418131-04223 | Start Date*: 2012-02-06 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A 12-Week, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Mometasone Furoate Metered Dose Inhaler in the Treatment of Children Ages 5 to 11 Years With Persistent Asthma | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) EE (Completed) HU (Completed) PL (Completed) GR (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005615-21 | Sponsor Protocol Number: 205.341 | Start Date*: 2006-07-13 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-Controlled, Crossover Efficacy and Safety Evaluation of 8-Week Treatment Periods of Two Doses [5 µg (2 actuations of 2.5 µg) and µg (2 actuations of 5 µg)] of Ti... | |||||||||||||
Medical condition: Patients with severe persistent asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005293-22 | Sponsor Protocol Number: D589GC00003 | Start Date*: 2014-08-06 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Phase 3, 12-Week, Double-Blind, Randomized, Parallel-Group, Multicenter Study Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 ug, 2 Actuations Twice Daily, and Symbicort pMDI 80... | ||
Medical condition: Asthma | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-000643-27 | Sponsor Protocol Number: MK-1029-012-00 | Start Date*: 2012-12-12 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Adaptive-Design, Dose-Ranging Study of MK-1029 in Adult Subjects with Persistent Asthma | |||||||||||||
Medical condition: Adult subjects 18 to 75 years of age with persistent asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001841-40 | Sponsor Protocol Number: GW685698X | Start Date*: 2005-10-05 |
Sponsor Name:GlaxoSmithKline Research And Development Ltd | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder 200mcg Twice-Daily, GW685698X Inhalation Powder ... | ||
Medical condition: Persistent asthma | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) LV (Prematurely Ended) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-023601-35 | Sponsor Protocol Number: FpS-AS-202 | Start Date*: 2012-01-11 |
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | ||
Full Title: A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Orally Twice Daily compared with Placebo in Adolescent and A... | ||
Medical condition: Severe Persistent Asthma | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) HU (Completed) BG (Completed) BE (Completed) GB (Completed) DE (Completed) PL (Completed) GR (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
